How does Nogo receptor influence demyelination and remyelination in the context of multiple sclerosis?

Rashidbenam, Zahra; Öztürk, Ezgi; Pagnin, Maurice; Theotokis, Paschalis; Grigoriadis, Nikolaos; Petratos, Steven

doi:10.3389/fncel.2023.1197492

Cited by 2 publications

(1 citation statement)

References 129 publications

(188 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, brain atrophy and cognitive impairment worsen from an early stage even without the recurrence of symptoms. Chronic "inflammation" is involved in the background of "demyelination" [198]. It is an intractable disease that cannot be completely cured.…”

Section: Discussionmentioning

confidence: 99%

Unraveling the Immunopathogenesis of Multiple Sclerosis: The Dynamic Dance of Plasmablasts and Pathogenic T Cells

Matsuzaka,

Yashiro

2023

Biologics

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system, characterized by multiple lesions occurring temporally and spatially. Additionally, MS is a disease that predominates in the white population. In recent years, there has been a rapid increase in the number of patients, and it often occurs in young people, with an average age of onset of around 30 years old, but it can also occur in children and the elderly. It is more common in women than men, with a male-to-female ratio of approximately 1:3. As the immunopathogenesis of MS, a group of B cells called plasmablasts controls encephalomyelitis via IL-10 production. These IL-10-producing B cells, called regulatory B cells, suppress inflammatory responses in experimental mouse models of autoimmune diseases including MS. Since it has been clarified that these regulatory B cells are plasmablasts, it is expected that the artificial control of plasmablast differentiation will lead to the development of new treatments for MS. Among CD8-positive T cells in the peripheral blood, the proportion of PD-1-positive cells is decreased in MS patients compared with healthy controls. The dysfunction of inhibitory receptors expressed on T cells is known to be the core of MS immunopathology and may be the cause of chronic persistent inflammation. The PD-1+ CD8+ T cells may also serve as indicators that reflect the condition of each patient in other immunological neurological diseases such as MS. Th17 cells also regulate the development of various autoimmune diseases, including MS. Thus, the restoration of weakened immune regulatory functions may be a true disease-modifying treatment. So far, steroids and immunosuppressants have been the mainstream for autoimmune diseases, but the problem is that this kills not only pathogenic T cells, but also lymphocytes, which are necessary for the body. From this understanding of the immune regulation of MS, we can expect the development of therapeutic strategies that target only pathogenic immune cells.

show abstract

Section: Discussionmentioning

confidence: 99%